Salvage Docetaxel for Pretreated Urothelial Cancer

Summary

Based on the previous clinical experience in other cancers, and considering the absence of current standard salvage regimens, the single agent docetaxel is selected as the regimen for this phase II study. Main toxicity of docetaxel is myelosuppression. The low rate of severe myelosuppression observed in other cancer trials warrants further study in urothelial cancer. The objective of the study is to evaluate the safety and activity of weekly docetaxel given as salvage therapy for advanced urothelial cancer.

Timeline

Start

2010-08

Primary completion

2013-04

Completion

2013-12

Drugs

Indications